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Abstract 
Objective: This study aimed to estimate the incidence of chronic kidney disease and its predictors among newly 
diagnosed type 2 diabetes patients attending St. Paul’s Hospital, Addis Ababa, Ethiopia.
Results: The overall incidence of chronic kidney disease was a major public health issue among type 2 diabetes mel-
litus patients with 2178 (95% CI 12,801, 21,286) cases per 10,000 patient-months. Moreover, 62(14.25%) patients in the 
sample experienced chronic kidney disease. Old age [adjusted hazard ratio (AHR) = 1.06, 95%CI 1.03, 1.09], no diabetic 
retinopathy [AHR = 0.13, 95%CI 0.07–0.24], high density lipoprotein cholesterol ≥ 40 mg/dl [AHR = 0.55, 95%CI 0.31, 
0.97] and high body mass index [AHR = 1.17, 95%CI 1.1, 1.25] were common factors for chronic kidney diseases.
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Introduction
Chronic kidney disease contributes substantially to 
human suffering and death [1]. For instance, the esti-
mated prevalence of people who have experienced CKD 
is 11–13% and 13.9% worldwide and sub-Saharan Africa 
respectively. chronic kidney disease is a critical issue in 
the management of patients with type 2 diabetes mellitus 
[1–5].
Previous studies in the area indicated that is mainly 
driven by diabetic mellitus (DM). For example, type 2 
diabetes mellitus (T2DM) causes 30–50% of CKD cases 
[6–10]. According to recent literature, CKD is more 
prevalent (11–29%) are among type 2 diabetic patients in 
developed than in developing countries [11–13]. A simi-
lar h study done in Hong Kong and South Africa reported 
a development of CKD among type 2 DM patients at a 
rate of 12.7 and 94.9%, respectively [14, 15]. Although 
the prevalence of CKD ranged from 2 to 41% in Africa 
[5, 16], the growing burden of CKD among type 2 DM 
patients is not well explored in low and middle-income 
countries [17–20].
Several studies highlighted the risk factors for CKD 
complication of type 2 diabetic patients. For example, 
age and sex were significant risk factors for CKD in type 
2 diabetic patients [21–23]. However, studies found dis-
parities in the risk factors for chronic kidney diseases 
[13, 22, 24–26]. In another cohort study, physical activ-
ity reduces the incidence [21], whereas smoking history 
and lipid abnormalities have increased the risk of CKD 
in type 2 DM patients [12, 27–31]. In another prospec-
tive study done among type 2 diabetic patients, factors 
such as high systolic blood pressure (SBP), low diastolic 
blood pressure (DBP) and high body mass index (BMI) 
significantly affected the CKD [12, 29, 32, 33]. Moreo-
ver, hypoglycemia, history of hypertension and diabetic 
retinopathy were considerable risks [5, 12, 22, 34–36]. 
A systematic review and meta-analysis revealed that BP 
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lowering medications and intensive blood-glucose con-
trol can reduce the risk of CKD [37, 38].
Previous studies showed that the incidence of diabetic 
kidney disease varied across countries. But this emerg-
ing global public health problem is not well investigated, 
rather it is overlooked in low-come countries including 
Ethiopia. Quantifying the burden of the disease and early 
detection of the risk factors is paramount in the preven-
tion of CKD. Therefore, this study aimed to estimate the 
incidence of chronic kidney disease and its predictors 
among newly diagnosed type 2 diabetes patients attend-
ing St. Paul’s Hospital, Addis Ababa, Ethiopia.
Main text
Methods
An institution-based retrospective follow-up study was 
conducted at St. Paul’s Hospital, Addis Ababa, Ethiopia. 
St. Paul’s Referral Hospital is found in the capital of Ethi-
opia, Addis Ababa. Since 1969 the hospital has been pro-
viding different medical care services included chronic 
problems like chronic kidney disease and supports to an 
estimated 200,000 people annually referred from all over 
the country.
All newly diagnosed T2DM patients who enrolled 
at St. Paul’s Referral Hospital between January 2008 
and November 2017 were considered in this study. The 
required sample (435) was determined by the incidence 
and predictors of CKD using STATA software. New 
T2DM diagnosed patients were eligible, while those who 
had CKD at the time of the diagnosis for T2DM were 
excluded from the study.
The data were collected using a standard extraction 
checklist which was adapted from the World Health 
Organization (WHO) guidelines [39]. After they were 
checked for completeness, data were entered using Epi 
Info 7 and exported to STATA 12 for further analysis. 
The outcome variable in this study was time to chronic 
kidney disease. Chronic kidney disease was defined as 
an estimated Glomerular Filtration Rate (eGFR) < 60 ml/
min/1.73 m2 estimated by the Cockcroft-Gault equation. 
Accordingly, participants were classified as either CKD 
cases or censored at the end of the study. Furthermore, 
the incidence of CKD was determined from the start of 
type 2 DM diagnosis until the last follow-up visit.
We used the Weibull Cox regression models to identify 
the predictors. Variables in the bi-variable proportional 
hazard model with a P-value below 0.2 were included in 
the multivariable analysis. For the overall model, Scaled 
Schoenfeld and Cox-Snell residuals plots were used to 
check the assumption. The most parsimonious model was 
chosen by Akaike’s Information Criterion (AIC). Finally, 
the crude and adjusted hazard ratio (HR) with its 95% CI 
was calculated to determine statistical significance.
Results
A total of 435 newly diagnosed T2DM patients were 
included in this study. Approximately half (50.6%) were 
females and only 101(23.2%) treated with insulin. More 
than half, 235(54%) had a history of hypertension, 404 
(92.9%) had no history of diabetic retinopathy, and 
261(66%) had a baseline LDL cholesterol level below 
100 mg/dl. Slightly more than half (50.5%) of the patients 
had less than 40 mg/dl HDL cholesterol level. Similarly, 
225(56.4%) had triglyceride level greater or equal to 
150 mg/dl and 259(64.6%) had less than 200 mg/dl total 
cholesterol level [Table 1].
The median time to develop CKD was 70.9  months 
with an interquartile range of (IQR: 41.00–88.73 months). 
The overall incidence rate of CKD was 2178 (95% CI 
12,801, 21,286) cases per 10,000 patient-month with 
total 28,466.13 patient-months observation. Moreover, 
the proportion of CKD among newly diagnosed T2DM 
patients was 14.25%.
The Kaplan–Meir curve showed that the chance of 
developing CKD for a patient who has T2DM increased 
over time. A large number of CKD diagnosed T2DM 
patients were observed between 60 and 80 months of the 
study period [Additional file 1]. Furthermore, a compari-
son of the survival functions of patients who had diabetic 
retinopathy complications showed a shorter CKD com-
plication time than patients who didn’t have (log-rank 
X2 = 67.4, P < 0.0001). Survival differences were also 
Table 1 Baseline factors of  newly diagnosed T2DM 
patients in St. Paul’s Hospital, Addis Ababa, from January 
2008 to April 2017
Variables Categories Frequency Percent
Sex Male 215 49.4
Female 220 50.6
Types of DM therapy Insulin 101 23.2
Oral 334 76.8
History of hypertension No 198 45.5
Yes 237 54.5
Anti-hypertensive therapy No 251 57.7
Yes 184 42.3
History of diabetic retinopathy No 404 92.9
Yes 31 7.1
LDL cholesterol, mg/dl < 100 261 66.0
≥ 100 135 34.0
HDL cholesterol, mg/dl < 40 200 50.5
≥ 40 196 49.5
Total cholesterol, mg/dl < 200 259 64.6
≥ 200 142 35.4
Triglyceride, mg/dl < 150 174 43.6
≥ 150 225 56.4
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observed in patients who had HDL Cholesterol level (log-
rank X2 = 14.07, P < 0.0001).
Based on AIC, Weibull Cox regression model was the 
most efficient model to describe the data (AIC = 243.2). 
According to the Schoenfeld residual global test, the 
overall full model satisfies the proportional hazard 
assumption (X2 = 6.04, P < 0.481). As well, the Cox Snell 
residual plot showed the proportional hazard assumption 
was satisfied (Fig. 1).
In multivariable, the Weibull Cox regression, age, his-
tory of diabetic retinopathy, high HDL cholesterol and 
BMI were significantly associated with the likelihood of 
CKD among type 2 diabetic patients.
The risk of developing CKD among newly diagnosed 
T2DM patients rose by 6% with a 1-year increase in age 
[AHR = 1.06, 95% CI 1.03–1.09]. The risk of developing 
CKD decreased by 87% [AHR = 0.13, 95% CI 0.07–0.24] 
among newly diagnosed T2DM with no history of dia-
betic retinopathy than patients with diabetic retinopathy. 
The risk of developing CKD decreased by 45% among 
newly diagnosed type 2 diabetic patients with high 
HDL cholesterol level (≥ 40  mg/dl) than patients with 
low HDL cholesterol level [AHR = 0.55, 95% CI 0.31–
0.97]. Furthermore, for a unit increase in BMI, the haz-
ard of developing CKD among newly diagnosed T2DM 
patients increases by 17% [AHR = 1.17, 95% CI 1.1–1.25] 
[Table 2].
Discussion
This study investigated the incidence and predictors of 
chronic kidney disease among newly diagnosed T2DM 
patients at St. Paul’s Hospital, Addis Ababa, Ethiopia.
In the study, the cumulative incidence of CKD 
was 2178 (95% CI 12,801, 21,286) cases per 10,000 
patient-months. This study revealed a higher incidence 
of CKD than the studies done in Hong Kong [14], Italy 
[11], Sweden [13] and Spain [35]. The differences could 
be attributed to the short follow up time used by the 
other studies and the variations in diagnostic methods 
applied. Moreover, the black race was associated with 
a greater rate of GFR decline which increases the inci-
dence of CKD [40]. However, it was lower than that of 
a study done in UK [12]. This could be due to the differ-
ence in the study design used by the U.K, which was a 
prospective follow up study.
In this study, we have found that age is a risk factor for 
CKD. The finding is consistent with those of studies con-
ducted in U.K [12], Taiwan [21], Japan [22], and Italy [41]. 
This might be because getting older age is associated with 
such risk factors CKD as cardiovascular diseases and 
obesity as well as endothelial cell dysfunction, activation 
of the sympathetic nervous system which promotes glo-
merulonephritis and chronic renal failure [42, 43]. This 
makes the mean change in eGFR decline with increases 
in age [44].
Patients with high BMI were significantly associated 
with CKD. The finding is inconsistent with those of stud-
ies conducted in Sweden [13], Italy [30, 45] and Israel 
[46]. The possible reason could be that an increased BMI 
promotes kidney damage through direct mechanisms like 
hemodynamic and hormonal effects. This might also lead 
to glomerular hyper fusion and glomerular hyper filtera-
tion; as a result, glomerular capillary pressure increases 
which may subsequently result in an increased urinary 
albumin excretion, followed by overt proteinuria and 
declining GFR [47]. Weight loss intervention is assistant 
for medical treatments to prevent or delay the progres-
sion of CKD in overweight or obese people with type 2 
diabetes [48].
This study found that the presence of diabetic retin-
opathy at baseline was a high risk for CKD. This finding 
is in line with those studies conducted in Japan [22] and 
UK [12]. This might be associated with the elevation of 
cardiac biomarkers and endothelial dysfunction which in 
turn lead to circulatory abnormalities increases proteinu-
ria and reduces vascular reactivity that reflects systemic 
factors associated with the development of CKD [49, 50].
In this study, we found that higher levels of HDL cho-
lesterol (≥ 40 mg/dl) were associated with a lower risk for 
CKD. This result was in concordance with those of stud-
ies conducted in Italy [30] and Japan [22]. Biologically, 
HDL cholesterol may be protective against the incidence 
of CKD. Moreover, type 2 diabetes patients might be pri-
marily involved in the reverse cholesterol transport and 
in a number of other non-cholesterol dependent effects, 
including anti-oxidant, anti-inflammatory, anti-throm-
botic and vasopressin effects. All of these beneficial 
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Fig. 1 Cox-Snell residuals for Weibull PH models of newly diagnosed 
T2DM patients in St. Paul’s Hospital, AA, from January 2008 to April 
2017
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vascular effects may also act to explain the lower risk of 
CKD incidence [30].
Conclusion
In this study, the incidence of CKD among type 2 DM 
patients was moderately growing burdens and seek pub-
lic concerns. Old age, high BMI, history of diabetic retin-
opathy and lower levels of HDL cholesterol were risk 
factors for the development of CKD. More attention and 
close monitoring should be exercised in order to control 
high BMI, high HDL cholesterol and diabetic retinopathy 
among the elderly.
Limitations
This investigation attempted to estimate the incidence 
of CKD and identify risk factors for the disease which 
may serve as input for policy and program designing in 
the context of a developing country. Indeed, this study 
included only type 2 diabetic patients who attended 
the hospital. Selection bias might have occurred if 
patients lived at home undiagnosed during the time. 
Additionally, the research did not investigate the behav-
ioral and institutional characteristics because they were 
not available in the hospital records, making it difficult 
to assess possible confounders. Therefore, the findings 
should be interpreted with this limitation in mind.
Additional file
Additional file 1. Kaplan–Meier cumulative hazard estimate of newly 
diagnosed T2DM patients at St. Paul’s Hospital, Ethiopia.
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Table 2 Multivariable analysis of  Weibull PH model for  newly diagnosed T2DM patients in  St. Paul’s Hospital, AA, 
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Variables Category CKD status Crude HR [95% CI] Adjusted HR [95% CI]
Censored Event
Sex Male 185 30 1
Female 188 32 0.94 (0.57, 1.54)
Age 1.07 (1.04, 1.09) 1.06 (1.03, 1.09)*
Diabetic retinopathy Yes 357 47 1 1
No 16 15 0.11 (0.06, 0.2) 0.13 (0.07, 0.24)*
History of hypertension No 174 26 1
Yes 199 36 1.18 (0.71, 1.95)
Hypertensive therapy No 213 38 1
Yes 160 24 0.83 (0.5, 1.4)
Types of DM therapy Insulin 85 16 1
Oral 288 46 0.96 (0.54, 1.7)
FBG(mg/dl) 0.99 (0.995, 1.002)
SBP (mmHg) 1.02 (1.01, 1.03)
DBP (mmHg) 1.03 (1.01, 1.05)
LDL cholesterol < 100 mg/dl 221 40 1
≥ 100 mg/dl 113 22 1.02 (0.61, 1.72)
HDL cholesterol < 40 mg/dl 155 45 1 1
≥ 40 mg/dl 179 17 0.35 (0.2, 0.62) 0.55 (0.31, 0.97)*
Total cholesterol < 200 mg/dl 221 38 1
≥ 200 mg/dl 118 24 1.09 (0.65, 1.8)
Triglyceride < 150 mg/dl 221 38 1
≥ 150 mg/dl 118 24 1.35 (0.81, 2.25)
BMI (kg/m2) 1.2 (1.1, 1.3)* 1.17 (1.1, 1.25)*
LR test χ2(6) = 96.7, P > χ2 = 0.0000, Log likelihood = − 113.6 AIC = 243.2
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